Results 131 to 140 of about 115,050 (245)

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials. [PDF]

Cancers (Basel), 2021
Zhang Y, Sharma A, Weiher H, Schmid M, Kristiansen G, Schmidt-Wolf IGH.   +5 more
europepmc   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

Advanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen, Zhao‐Yu Liu, Gao‐Wen Qu, Run‐Hao Zeng, Wen‐Xia Yao, Yong‐Bing Zhou, Xue Liang, Yu‐Xiong Lai   +7 more
wiley   +1 more source

Effects of interleukin-2 concentration and administration method on proliferation and function of cytokine-induced killer cells. [PDF]

Transl Cancer Res, 2021
Liu Y, Li J, Zhao L, Zhu J, Liu S, Wang H, Zhang Y.   +6 more
europepmc   +1 more source

Lactoferrin Deficiency During Lactation Causes Adult Obesity‐Related Metabolic Disease Through Persistent Adipose Dysfunction Driven by Impaired Adipocyte Development

Advanced Science, EarlyView.
Lactational lactoferrin deficiency exerts lasting effects on epididymal adipose tissue development from lactation into adulthood: it impairs adipocyte hyperplasia and induces pathological hypertrophy, resulting in lower body weight yet exacerbated metabolic dysfunction under a high‐fat diet in adulthood.
Qin An, Yunxia Zou, Wenli Wang, Zhimei Cheng, Zhuoxing Zhang, Ruwei Liu, Xiong Wang, Kunlun Huang, Fangrong Ding, Yunping Dai, Qingyong Meng, Yali Zhang   +11 more
wiley   +1 more source

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer. [PDF]

Front Oncol, 2022
Ma B, Zhou Y, Shang Y, Zhang Y, Xu B, Fu X, Guo J, Yang Y, Zhang F, Zhou M, Huang H, Li F, Lin H, Zhao L, Wang Z, Gao Q.   +15 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells. [PDF]

Stem Cells Int, 2023
Dong M, Zhang G, Meng J, Liu B, Jiang D, Liu F.   +5 more
europepmc   +1 more source

Supramolecular Assembly of Stepped‐Persistent ROS Nanogenerator for Sustained Tumor Immunotherapy

Advanced Science, EarlyView.
ROS catalytic systems often fail to achieve both effective tumor elimination and persistent immune activation due to their monotonous ROS production profiles. A stepped‐persistent ROS nanogenerator was developed by supramolecularly assembling multiple ROS generation modules within a nanofiber structure to simultaneously extend ROS generation duration ...
Zhenqiang Wang, Ming Qin, Wenjing Lai, Shiwen Chen, Fengling Wang, Dandan Xie, Maohua Chen, Changpeng Hu, Kui Wang, Rong Zhang, Guobing Li   +10 more
wiley   +1 more source

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. [PDF]

J Immunother Cancer, 2021
Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A.   +14 more
europepmc   +1 more source